We are working to develop a new diagnostic platform that provides accurate and timely diagnoses of neurodegenerative diseases

One in four neurodegenerative diseases are initially misdiagnosed. This means that patients don't always get the treatment they need, and introduces uncertainty about the future.

Tim Chisholm is completing his PhD at the University of Cambridge, and has expertise in assay development and exploring biomarkers in neurodegenerative disease.